Vetirus Selected as Spotlight Presenter at Vet Health Global

FOR IMMEDIATE RELEASE

Vetirus Pharmaceuticals Selected as Spotlight Presenter at Vet Health Global 2025 to Introduce Revolutionary Hydrophobic Surgical Glue, Zonexias Hemorapid

Charlottetown, Prince Edward Island, Canada – June 3, 2025 – Vetirus Pharmaceuticals, a leader in innovative veterinary solutions based in Naples, FL and London, UK, is excited to announce its selection as a Spotlight Presenter at the Vet Health Global 2025 conference, taking place June 24-26, 2025, in Charlottetown, Prince Edward Island, Canada. Vetirus will introduce its groundbreaking product, Zonexias Hemorapid, a revolutionary hydrophobic surgical glue poised to transform veterinary surgery.

The Vet Health Global conference, North America’s premier animal health and nutrition business event, unites industry leaders, innovators, investors, and regulators to explore cutting-edge advancements and forge strategic partnerships. As part of the conference’s Innovation Spotlight sessions, Vetirus Pharmaceuticals will showcase Zonexias Hemorapid, a late pre-commercial phase technology set to redefine wound closure standards in veterinary medicine.

Zonexias Hemorapid is a next-generation hydrophobic surgical glue offering superior adhesion, rapid application, and exceptional durability in challenging surgical environments. Addressing limitations of traditional sutures and adhesives, this innovative product provides veterinarians with a fast, reliable, and minimally invasive solution for wound closure, reducing procedure times and enhancing patient recovery. Its unique hydrophobic properties ensure robust performance in moist conditions, making it a game-changer for both surgical and emergency applications.

“We are thrilled to be selected as a Spotlight Presenter at Vet Health Global 2025,” said Robert N. Jordan, CEO of Vetirus Pharmaceuticals. “Zonexias Hemorapid represents a major advancement in veterinary surgical technology, and we are eager to share its potential with global industry leaders and collaborators. This platform offers a unique opportunity to connect with partners who share our commitment to advancing animal health through innovation.”

The Innovation Spotlight sessions at Vet Health Global 2025 will highlight emerging companies with breakthrough technologies, providing Vetirus a prime opportunity to engage with key stakeholders and explore partnerships to bring Zonexias Hemorapid to market. Hosted by PEI BioAlliance, the conference is renowned for driving innovation and collaboration in the animal health industry.

For more information about Vetirus Pharmaceuticals and Zonexias Hemorapid, or to schedule a meeting with the Vetirus team at Vet Health Global 2025, please contact:

Media Contact:
Bailey Anderson
Director of Communications, Vetirus Pharmaceuticals
Email: contact@vetirus.com
Phone: (239) 298-1183 

About Vetirus Pharmaceuticals
Vetirus Pharmaceuticals is a pioneer in veterinary medicine, dedicated to developing advanced solutions that improve animal health and well-being. With a focus on innovative technologies and regenerative medicine, Vetirus addresses unmet needs in veterinary care through products like Zonexias Hemorapid, designed to enhance surgical outcomes and patient recovery.

About Vet Health Global
Vet Health Global is the leading international animal health and nutrition business conference, held biennially in Charlottetown, Prince Edward Island, Canada. The event brings together senior executives, emerging companies, investors, regulators, and researchers to explore market trends, regulatory issues, and innovative developments in companion and food animal health. For more information, visit www.vethealthglobal.com.

Contact for Vet Health Global 2025:
PEI BioAlliance
134 Kent Street, Suite 302, Charlottetown, Prince Edward Island, Canada C1A 8R8
Tel: 902-367-4400
Email: info@vethealthglobal.com